Eva‐Maria Gamper

3.0k total citations
69 papers, 2.0k citations indexed

About

Eva‐Maria Gamper is a scholar working on Oncology, Economics and Econometrics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Eva‐Maria Gamper has authored 69 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Economics and Econometrics and 14 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Eva‐Maria Gamper's work include Health Systems, Economic Evaluations, Quality of Life (26 papers), Cancer survivorship and care (23 papers) and Economic and Financial Impacts of Cancer (12 papers). Eva‐Maria Gamper is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (26 papers), Cancer survivorship and care (23 papers) and Economic and Financial Impacts of Cancer (12 papers). Eva‐Maria Gamper collaborates with scholars based in Austria, Australia and Germany. Eva‐Maria Gamper's co-authors include Bernhard Holzner, Johannes M. Giesinger, Georg Kemmler, Anne Oberguggenberger, August Zabernigg, Barbara Sperner‐Unterweger, Lisa M. Wintner, Gerhard Rumpold, Susanne Singer and Madeleine King and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, JNCI Journal of the National Cancer Institute and The Lancet Oncology.

In The Last Decade

Eva‐Maria Gamper

69 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva‐Maria Gamper Austria 27 755 373 290 285 262 69 2.0k
Josephine M. Norquist United States 25 279 0.4× 213 0.6× 225 0.8× 253 0.9× 408 1.6× 70 2.2k
Tom Young United Kingdom 27 1.1k 1.5× 213 0.6× 44 0.2× 599 2.1× 239 0.9× 93 2.4k
Carol Fairchild United States 17 138 0.2× 325 0.9× 434 1.5× 499 1.8× 283 1.1× 28 2.8k
Karen Welch United Kingdom 22 274 0.4× 171 0.5× 116 0.4× 224 0.8× 316 1.2× 40 1.8k
Douglas Einstadter United States 23 105 0.1× 203 0.5× 87 0.3× 191 0.7× 226 0.9× 59 1.4k
Anne Oberguggenberger Austria 18 439 0.6× 50 0.1× 47 0.2× 186 0.7× 126 0.5× 43 1.0k
Deborah Fitzsimmons United Kingdom 26 724 1.0× 184 0.5× 59 0.2× 307 1.1× 525 2.0× 88 2.2k
Gro Berntsen Norway 30 354 0.5× 89 0.2× 307 1.1× 280 1.0× 304 1.2× 65 2.3k
Karla Gough Australia 26 895 1.2× 60 0.2× 28 0.1× 445 1.6× 165 0.6× 105 2.2k
Karen E. Bremner Canada 29 483 0.6× 649 1.7× 40 0.1× 258 0.9× 186 0.7× 95 2.2k

Countries citing papers authored by Eva‐Maria Gamper

Since Specialization
Citations

This map shows the geographic impact of Eva‐Maria Gamper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva‐Maria Gamper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva‐Maria Gamper more than expected).

Fields of papers citing papers by Eva‐Maria Gamper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva‐Maria Gamper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva‐Maria Gamper. The network helps show where Eva‐Maria Gamper may publish in the future.

Co-authorship network of co-authors of Eva‐Maria Gamper

This figure shows the co-authorship network connecting the top 25 collaborators of Eva‐Maria Gamper. A scholar is included among the top collaborators of Eva‐Maria Gamper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva‐Maria Gamper. Eva‐Maria Gamper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gamper, Eva‐Maria, Madeleine King, Anja Schiel, et al.. (2025). Shifting perspectives: a reflection on cancer-specific quality-of-life metrics in cancer care economics. The Lancet Oncology. 26(5). 545–547. 1 indexed citations
2.
Norman, Richard, et al.. (2024). Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma. The European Journal of Health Economics. 26(5). 721–733. 3 indexed citations
3.
Singer, Susanne, Georgios Ioannidis, Gerasimos P. Sykiotis, et al.. (2024). The Cancer-Specific Health Economic Measure QLU-C10D is Valid and Responsive for Assessing Health Utility in Patients with Thyroid Cancer. Thyroid. 34(11). 1356–1370. 2 indexed citations
4.
5.
Musoro, Jammbe, Corneel Coens, Mirjam A. G. Sprangers, et al.. (2023). Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. European Journal of Cancer. 188. 171–182. 64 indexed citations
6.
Ramage, John, Elizabeth Friend, Barbara King, et al.. (2022). Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). Journal of Neuroendocrinology. 34(4). e13097–e13097. 4 indexed citations
7.
Gamper, Eva‐Maria, Fabio Efficace, Juan Ignacio Arrarás, et al.. (2022). EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals. BMC Public Health. 22(1). 1040–1040. 17 indexed citations
8.
Efficace, Fabio, David Cella, Neil K. Aaronson, et al.. (2021). Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials. JNCI Journal of the National Cancer Institute. 114(3). 471–474. 20 indexed citations
9.
Gamper, Eva‐Maria, Francesco Cottone, Kathrin Sommer, et al.. (2021). The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology. 137. 31–44. 20 indexed citations
10.
Finch, Aureliano Paolo, Eva‐Maria Gamper, Richard Norman, et al.. (2021). Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment. PharmacoEconomics. 39(9). 1085–1098. 22 indexed citations
11.
Gamper, Eva‐Maria, Bernhard Holzner, Madeleine King, et al.. (2018). Test-Retest Reliability of Discrete Choice Experiment for Valuations of QLU-C10D Health States. Value in Health. 21(8). 958–966. 30 indexed citations
12.
Gamper, Eva‐Maria, Virginie Nerich, Monika Sztankay, et al.. (2017). Evaluation of Noncompletion Bias and Long-Term Adherence in a 10-Year Patient-Reported Outcome Monitoring Program in Clinical Routine. Value in Health. 20(4). 610–617. 10 indexed citations
13.
Norman, Richard, Rosalie Viney, Daniel Costa, et al.. (2016). Two New Cancer-Specific Multi-Attribute Utility Instruments: EORTC QLU-C10D and FACT-8D. Value in Health. 19(7). A807–A807. 4 indexed citations
14.
Nerich, Virginie, et al.. (2016). Cost–utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Research and Treatment. 159(3). 407–424. 15 indexed citations
15.
Gamper, Eva‐Maria, Morten Aagaard Petersen, Neil K. Aaronson, et al.. (2016). Development of an item bank for the EORTC Role Functioning Computer Adaptive Test (EORTC RF-CAT). Health and Quality of Life Outcomes. 14(1). 72–72. 31 indexed citations
16.
Petersen, Morten Aagaard, Eva‐Maria Gamper, Anna Costantini, et al.. (2015). An emotional functioning item bank of 24 items for computerized adaptive testing (CAT) was established. Journal of Clinical Epidemiology. 70. 90–100. 17 indexed citations
17.
Zabernigg, August, Johannes M. Giesinger, Georg Pall, et al.. (2012). Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC Cancer. 12(1). 390–390. 32 indexed citations
18.
Giesinger, Johannes M., Lisa M. Wintner, Anne Oberguggenberger, et al.. (2011). Quality of Life Trajectory in Patients with Advanced Cancer during the Last Year of Life. Journal of Palliative Medicine. 14(8). 904–912. 65 indexed citations
19.
Gamper, Eva‐Maria, Johannes M. Giesinger, Anne Oberguggenberger, et al.. (2011). PCN146 Good Prognosis, Good Quality of Life? – Longitudinal Assessment of Quality of Life in Thyroid Cancer Patients. Value in Health. 14(7). A461–A461. 1 indexed citations
20.
Oberguggenberger, Anne, Beate Beer, Herbert Oberacher, et al.. (2011). Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Research and Treatment. 128(2). 553–561. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Josephine M. Norquist Breakdown of academic impact, for papers by Tom Young Breakdown of academic impact, for papers by Carol Fairchild Breakdown of academic impact, for papers by Karen Welch Breakdown of academic impact, for papers by Douglas Einstadter Breakdown of academic impact, for papers by Anne Oberguggenberger Breakdown of academic impact, for papers by Deborah Fitzsimmons Breakdown of academic impact, for papers by Gro Berntsen Breakdown of academic impact, for papers by Karla Gough Breakdown of academic impact, for papers by Karen E. Bremner
Rankless by CCL
2026